Nephrology

Investigators conclude improvements in kidney transplantation may require significant interventions.

The new study underscores the importance of annual urine analysis to catch signs of diabetic nephropathy.

New WORLDSymposium findings show a treated patient had 100% reduction in the accumulating fatty substrate associated with the burdensome rare disease after 1 year.

The adverse effects of corticosteroids have underscored a need to eliminate the drug from treatment regimens.

The University of Chicago hypertension expert discusses new ADA recommendations for cardiovascular risk management.

The treatment represents the first ever oral therapy approved by the FDA for lupus nephritis.

Using piperacillin/tazobactam increases the risk for acute kidney injury, and this risk can be exacerbated by concurrent vancomycin.

If approved, the treatment would be the first SGLT2 inhibitor for patients with chronic kidney disease.

Patients who continue RAS therapy had a lower risk of kidney replacement therapy.

The SGLT2 inhibitor demonstrated possible erythropoietic effects in type 2 diabetes patients.

The first approved generic product for injection glucagon is also indicated for diagnostic use, when appropriate.

FibroGen will submit additional data for the New Drug Application.

There was not a statistically significant difference in eGFR between kidney recipients of HCV positive and negative donors.

Dr. Gerald Shulman discusses how diabetes can eventually be reversed.

By addressing insulin resistance, researchers believe they can reduce the comorbidities associated with type 2 diabetes.

Dr. Giorgino discusses how combining SGLT2 Inhibitors and GLP-1RA could be combined for treating type 2 diabetes.

More studies are planned testing the impact of finerenone.

Finerenone could be another option to SGLT2 inhibitors for this patient population.

The indication comes from collaborative work among experts and community leaders coordinated by the Oxalosis & Hyperoxaluria Foundation and the Kidney Health Initiative.

A week-long treatment program prevented HCV transmission in 88% of cases.

New phase 1 data show the first-in-class oral therapy is not affected by the burden on metabolism via hepatic or renal disease.

In data presented during Kidney Week, researchers find the risk of developed an acute kidney injury increased in both sickle cell trail and sickle cell disease patients.

The absolute SCr criterion correlated better with all-cause mortality than the relative increase in serum creatinine.

Length of stay, cost, and the mortality rate all increase among patients with chronic kidney disease compared to patients who do not suffer from CKD.

Dr. Kliger discusses how nephrologists can safely treat patients this winter.